We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Partnership to Develop Injectable Tracer for Diagnosing, Tumor Surgery

By HospiMedica International staff writers
Posted on 06 Apr 2011
Five French partners are developing an injectable tracer that can provide both nuclear imaging in the preoperative evaluation of tumors and optical imaging during ablation or biopsy. More...


CEA-Leti (Grenoble, France) and three other French partners reported that the three-year Nano-ENO project is developing a specific tracer using a patented organic nanocarrier (Lipidot). To improve its targeting capacities, a peptide molecule that recognizes specific types of cancer will also be grafted to the Lipidots. CEA-Leti conducts research and develops nanoelectronics and technology for healthcare. The Nano-Eno project includes Advanced Accelerator Applications (Saint-Genis-Pouilly, France), Fluoptics (Grenoble, France), and VetAgro Sup (Marcy-l'Etoile, France), as well as Frédéric Joliot Hospital (Orsay, France).

When treating cancer, clinicians utilize several diagnostic tools and surgical aids, including positron emission tomography (PET) scan and fluorescence imaging. A PET scan is a nuclear imaging technology that allows radiologists to measure the metabolic activity of an organ by injecting a radiotracer and then examining the gamma rays that are emitted as the tracer disintegrates.

Fluorescence imaging is a comparatively new technology that combines the use of a florescent tracer with near-infrared spectroscopy (NIRS). The resulting real-time images help surgeons obtain cleaner margins during surgery and therefore reduce the risk of recurrence.

The nuclear imaging markers used in a PET scan help provide high-resolution images, while optical contrast agents facilitate the identification of tumor cells in real-time. Combining these imaging technologies makes it possible to confirm that the tumors being operated on correspond to the tumors identified in the preoperative studies. It also allows for a more thorough procedure to be performed with reduced overall surgical time; not only can the surgeon perform more rapidly and with greater precision, but the entire operation is streamlined, allowing for a more efficient use of operating rooms and surgical staff.

This project will receive support from the Cancéropôle Lyon Auvergne Rhône Alpes (CLARA; France) Preuve de Concept (Proof of Concept) initiative for three years.

CEA is a French government-funded technologic research organization. A prominent player in the European research area, it is involved in setting up collaborative projects with many partners worldwide. The CEA is based in 10 research centers in France, each specializing in specific fields. The laboratories are located in the Paris region, the Rhône-Alpes, the Rhône valley, the Provence-Alpes-Côte d'Azur region, Aquitaine, Central France, and Burgundy.

Related Links:

CEA-Leti



Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image: The findings suggest that hematopoietic cell transplantation may benefit patients with Shwachman-Diamond syndrome soon after high-risk features are detected, before advanced malignancy develops. (Image Credit: Shutterstock)

Early Stem Cell Transplantation May Improve Survival in Rare Inherited Bone Marrow Disorder

Shwachman-Diamond syndrome (SDS) is a rare inherited bone marrow disorder that can progress to severe hematologic disease. More than 90% of affected children survive beyond age 20, but fewer than 30% live... Read more

Surgical Techniques

view channel
Image: Memo 4D Curve preserves the mitral annulus’s natural three-dimensional motion while supporting remodeling and is available in sizes up to 42 mm for a broad range of mitral pathology. (Photo courtesy of Corcym)

First Human Implant Performed With New Open Mitral Annuloplasty Ring

In mitral valve repair, clinicians aim to preserve the mitral annulus’s three-dimensional motion while providing enough support for effective remodeling. Ring preferences vary between open and closed ... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.